Clinical Trial Update: AG-120 in People With IDH1 Mutant Chondrosarcoma [Phase 2]

View source ↗

Summary

This update describes a Phase 2 study of AG-120 (ivosidenib) in patients with IDH1-mutant chondrosarcoma, with the trial currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma

Drugs mentioned

• AG-120 (ivosidenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Chondrosarcoma, Chondrosarcoma, Grade 2 | Phase 2 | Status: ACTIVE_NOT_RECRUITING